A new anti-cancer drug developed by researchers at Oregon Health & Science University is the first to treat maternal fetal medicine in babies, using a new type of cancer treatment called a “clustering” technique.
The researchers found that using this technique, they were able to successfully treat up to 70 percent of all cancerous tumours in newborns.
The new drug, called Myriad-P, was developed by the Oregon Health Sciences University and the Oregon Institute of Science & Medicine, and is currently being evaluated by the Food and Drug Administration (FDA).
The FDA approved Myriad for use in pregnant women and the FDA says that Myriad is safe and effective in adults.
The researchers tested the drug against three types of tumours: breast, cervical, and colorectal cancers.
The research team, led by Oregon Health scientist Amy K. Kuehl and colleagues, says that using Myriad can help reduce the incidence of cancerous and non-cancerous cells in the mother’s body, but only in the case of breast, colorecctal, and cervical cancers.
In addition, the drug is also helpful in other types of cancer, including those that are caused by other types or in patients with other types.
The drug is available as a two-week pill or as a six-week tablet.
The study involved 1,741 women between the ages of 17 and 43 who were diagnosed with breast, colon, lung, ovarian, or uterine cancer, and were taking anti-proliferative drugs such as the anti-viral drug, tacrolimus.
Researchers measured the amount of cells in women’s breast tissue, as well as the size of the tumours.
The most common type of breast cancer was found to be colon, which accounted for more than 90 percent of the cases, followed by cervical, lung and ovarian cancers.
The researchers also found that the tumour was growing at an alarming rate.
In contrast, about two-thirds of the colorecmal and uterine tumours were benign and only one-third of the cervical and ovarian tumours had abnormal growth.
The drugs also slowed down tumour growth.
The anti-clustered drug significantly reduced the amount and size of cells found in tumours and slowed down their growth.
In women who were taking tacrolamine, the anti clustered drugs did not significantly slow the growth of cancer cells, but did slow down their progression.
However, the researchers said that the drugs also decreased the tumorous growth in the mothers who took them.
In their report, the team said that although the anti clotrimaxant was well tolerated in pregnant woman, it had no effect on breast cancer in the infant.
The report was published in the journal Nature Medicine.